NCT04178005
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
At risk: Primary completion moved 9 months later.
See at-risk trials from University of Texas Southwestern Medical Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 11 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Aug 30, 2026 to May 30, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 29 words
- Study completion pushed from Dec 2026 to Aug 2027
- Secondary endpoints: details revised at 1 of 1 entry
- Publications: details revised at 36 of 39 entries
- Notable Primary completion date: Aug 30, 2024 to Aug 30, 2026v12
- Minor Study sites: 1 to 2v11
- Minor Study completion date: Dec 2024 to Dec 2026
- Study description expanded, about 59 words
- Notable Primary completion date: Aug 30, 2022 to Aug 30, 2024
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised
Show 5 earlier versionsHide 5 earlier versions
- Minor Primary completion date: Jul 1, 2022 to Aug 30, 2022v8
- Minor Primary completion date: Mar 2022 to Jul 1, 2022
- Study completion date: Dec 2022 to Dec 2024
- Notable Eligibility criteria expanded, about 2 wordsv6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria shortened, about 7 words
- Start date changed from estimate of Mar 2020 to Feb 19, 2020
- Site details revised
Notable Eligibility criteria expanded, about 14 wordsv3 Show 4 more changesShow less
- Primary endpoint revised
- Secondary endpoints: 2 to 1
- Study description shortened, about 365 words
- Publications: details revised at 39 of 39 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI. Each treatment course is divided into 2 treatment cycles: * Administration of first treatment course (year 1 treatment): * First cycle: Starts on Day 1 of the study * Second cycle: Administered 23 to 27 days after the last dose of first cycle. * Administration of second treatment course (year 2 treatment): * First cycle: Administered at least 43 weeks after the last dose of year 1 treatment * Second cycle: Administered 23 to 27 days after the last dose of first cycle of year 2 treatment. The cycle dosage will be administered as 1 or 2 cladribine 10 mg tablets daily over 4 or 5 consecutive days.
Drugs: Cladribine
Sites
2 sites in 1 country